Apollo Biologics

Apollo Biologics is a specialized consulting firm offering end-to-end development support for biologic drugs, including monoclonal antibodies, peptides, conjugates, and viral-based products. The company's core services encompass regulatory strategy from IND through BLA, CMC and bioanalytical assay design/validation, and confidential due diligence for licensing and M&A. Led by founder Dr. Constance Cullen, the firm capitalizes on over 20 years of industry experience and a track record of successful regulatory submissions across oncology, immunology, metabolic diseases, and biosimilars. It operates as a service provider, not a drug developer, positioning itself as a strategic partner to accelerate and de-risk client programs.

Integrated consulting platform offering expertise in bioanalytical assay development/validation, CMC strategy for biologics, regulatory intelligence, and GLP/GMP compliance oversight. No proprietary therapeutic technology.

Competes with a fragmented array of small, specialist consultancies and larger global Contract Research Organizations (CROs) that offer regulatory and CMC services. Differentiation is based on deep, niche expertise, a proven track record in successful submissions, and the high-touch, senior-level engagement of its founder.